EMA scales back activities ahead of Brexit

The European Medicines Agency (EMA) has announced plans to temporarily further scale back and suspend activities in order to cope with a more significant staff loss from the agency’s relocation than was originally expected.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Teva faces scrutiny over efforts to curb generic competition

27 August 2026 Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers.

Pharma

Teva and Aurinia settle generics dispute over lupus drug, voclosporin

21 August 2026 Under the terms of the agreement, which resolves all patent litigation between the biopharma rivals, Teva now has a launch date for its own version of Aurinia's Lupkynis.

Pharma

SK Biopharmaceuticals settles epilepsy generic dispute

20 August 2026 A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products.

More features

Top law firms and individuals recognised in WIPR’s UK Patent Rankings 2026

Teva faces scrutiny over efforts to curb generic competition

FDA targets faster generic approvals in drive to slash drug prices

China-origin biotech assets and the hidden question of IP ownership

Paul, Weiss finds appellate ‘star’ to lead Supreme Court practice

The buyers' wishlist: What makes a life sciences deal stack up?

UK appoints ex-engineer as new intellectual property Minister

Stris & Maher opens new Dallas office with partner hires

EMA scales back activities ahead of Brexit

More on this story

Editor's picks

Editor's picks

More features